Summary

Despite the clinical success of venetoclax in acute myeloid leukemia, resistance remains a major barrier to long-term patient outcomes. This whitepaper introduces a validated panel of venetoclax-resistant AML cell models—engineered to mirror the resistance seen in the clinic. Designed as a ready-to-use platform, these models empower researchers to rapidly assess novel combination strategies, next-generation inhibitors, and mechanistic hypotheses without the costly, time-consuming process of generating resistant lines from scratch. With both in vitro and in vivo characterization, this platform bridges the gap between discovery and translational evaluation, offering a practical shortcut to advancing more durable therapies.

• Clinically relevant resistance models: Derived from RS4;11, MOLM-13, and MV-4-11 lines with >160 fold resistance maintained in vivo
• Accelerated drug evaluation: Skip internal model generation and test candidates directly in a resistance setting
• Actionable biology: Enables mechanistic studies, biomarker discovery, and combination regimen screening
• Proven utility: Demonstrates how MCL1 inhibition restores venetoclax sensitivity, validating the platform’s predictive power

Download the full whitepaper to see how these resistant models can de risk and fast track your AML drug development programs.